RxDoctor Payments Data

Emma Heller, PA

Physician Assistant · Orwigsburg, PANPI 1285304956

Payments from drug & device makers

$4,318in general payments, 2019–2025

Across 52 payments — averaging $83.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Gilead$332
  • Regeneron Healthcare Solutions, Inc.$312
  • Intra-sana Laboratories$292
  • Intercept Pharmaceuticals, Inc.$278
  • E.r. Squibb & Sons, L.L.C.$261
  • plus $973 from 8 others

What the payments were for

  • Food & beverage$4,21898%
  • Gifts$1002%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,318 in reported general payments places this provider in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$19,289
Medicare patients
125
Services billed
172

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide61$43,952
Mesalamine15$12,023
Dexlansoprazole DrDexlansoprazole18$5,908
Sucralfate20$5,226
Omeprazole250$3,118
Pantoprazole Sodium217$3,098
Famotidine128$2,128
Colestipol Hcl15$1,302
Esomeprazole Magnesium22$1,235
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11$723
Dicyclomine Hcl30$430
Metronidazole17$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,869$43,95261 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Orwigsburg

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →